Weight Loss Management

Semaglutide (brand name Wegovy) is an FDA-approved medication for chronic weight management. It works by mimicking a natural hormone in the body called GLP-1 (glucagon-like peptide-1), which helps regulate appetite and eating behavior.

​

By acting on this pathway, semaglutide helps reduce hunger, slow stomach emptying, and increase feelings of fullness after eating. Many patients also notice a decrease in “food noise,” making it easier to make healthier food choices and maintain portion control.

When combined with a reduced-calorie diet and regular physical activity, semaglutide can support meaningful and sustained weight loss, along with improvements in overall metabolic health.

​

Semaglutide is typically prescribed for:

• Adults with a BMI of 30 or higher (obesity), or

• Adults with a BMI of 27 or higher who also have a weight-related condition such as high blood pressure, diabetes, or high cholesterol

​

Summary:
— Mechanism: Mimics GLP-1 to reduce appetite, slow gastric emptying, and increase satiety
— Use: Approved for long-term weight management in individuals with obesity or overweight with related health conditions
— Benefits: Clinically significant weight loss, improved metabolic health, and better appetite control

Tirzepatide (brand name Zepbound) is an FDA-approved medication for chronic weight management. It works by activating two natural hormone pathways in the body—GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)—which play key roles in regulating appetite, metabolism, and blood sugar.

​

By targeting both of these pathways, tirzepatide helps reduce hunger, increase feelings of fullness, and decrease “food noise,” making it easier to control portions and maintain a healthier eating pattern.

​

When combined with a reduced-calorie diet and regular physical activity, tirzepatide can lead to significant and sustained weight loss, along with improvements in metabolic health.

​

Tirzepatide is typically prescribed for:

• Adults with a BMI of 30 or higher (obesity), or

• Adults with a BMI of 27 or higher who also have a weight-related condition such as high blood pressure, diabetes, or high cholesterol

​

It is also FDA-approved for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

​

Summary:
— Mechanism: Dual GIP and GLP-1 receptor activation to reduce appetite, increase satiety, and improve metabolic regulation
— Use: Approved for long-term weight management in adults with obesity or overweight with related health conditions
— Benefits: Significant weight loss, improved metabolic health, and treatment of obstructive sleep apnea in appropriate patients